Difenoxin

Jump to: navigation, search
Difenoxin.png
Difenoxin
Systematic (IUPAC) name
1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylic acid
Identifiers
CAS number 35607-36-4
ATC code A07DA04
PubChem 34328
DrugBank DB01501
Chemical data
Formula C28H28N2O2 
Mol. mass 424.53 g/mol
SMILES eMolecules & PubChem
Synonyms Difenoxin, Motofen
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status

Controlled (S8)(AU) ?(US)

Routes  ?

WikiDoc Resources for Difenoxin

Articles

Most recent articles on Difenoxin

Most cited articles on Difenoxin

Review articles on Difenoxin

Articles on Difenoxin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Difenoxin

Images of Difenoxin

Photos of Difenoxin

Podcasts & MP3s on Difenoxin

Videos on Difenoxin

Evidence Based Medicine

Cochrane Collaboration on Difenoxin

Bandolier on Difenoxin

TRIP on Difenoxin

Clinical Trials

Ongoing Trials on Difenoxin at Clinical Trials.gov

Trial results on Difenoxin

Clinical Trials on Difenoxin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Difenoxin

NICE Guidance on Difenoxin

NHS PRODIGY Guidance

FDA on Difenoxin

CDC on Difenoxin

Books

Books on Difenoxin

News

Difenoxin in the news

Be alerted to news on Difenoxin

News trends on Difenoxin

Commentary

Blogs on Difenoxin

Definitions

Definitions of Difenoxin

Patient Resources / Community

Patient resources on Difenoxin

Discussion groups on Difenoxin

Patient Handouts on Difenoxin

Directions to Hospitals Treating Difenoxin

Risk calculators and risk factors for Difenoxin

Healthcare Provider Resources

Symptoms of Difenoxin

Causes & Risk Factors for Difenoxin

Diagnostic studies for Difenoxin

Treatment of Difenoxin

Continuing Medical Education (CME)

CME Programs on Difenoxin

International

Difenoxin en Espanol

Difenoxin en Francais

Business

Difenoxin in the Marketplace

Patents on Difenoxin

Experimental / Informatics

List of terms related to Difenoxin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Difenoxin (Motofen, R-15403) is a 4-phenylpiperidine derivative that is related to the opioid analgesic drug pethidine (meperidine) and more distantly related to alphaprodine and piritramide, and it is an active metabolite of the anti-diarrhoea drug diphenoxylate. Difenoxin et al. have a high peripheral/central actions ratio, working primarily on various opioid receptors in the intestines.[1] Difenoxin was developed in 1970 in Belgium at Janssen Pharmaceutica.

Related compounds

Loperamide (Imodium) is also closely related to difenoxin in chemical structure but does not cross the blood–brain barrier as does difenoxin, and the combination drug diphenoxylate hydrochloride with atropine sulfate (Lomotil) is the prototype of this four-member subfamily of the synthetic opioid receptor agonists and sub-category of opioid anti-diarrhoeals. Pethidine was serendipitously discovered in research during the 1930s on gastrointestinal drugs to serve as alternatives to belladonna and opium derivatives, but the anti-diarrhoeal effects of pethidine are less than those of this subclass and equivalent constipating doses of pethidine have prominent central actions. Therefore, with difenoxin and related drugs, the ratio of GI effects to central narcotic effects is particularly high, which makes it an attractive alternative in the minds of many to the other opioids used for diarrhoea, viz. codeine, morphine, dihydrocodeine, paregoric, laudanum and opium . The parent of the three above-mentioned pethidine-related anti-diarrhoeals is diphenoxylic acid, which can also be manufactured and used pharmaceutically.

Legal status

Difenoxin is a Schedule I drug by itself (Lyspafen) in the USA.[2] It has been approved for use in the late 1990s in the form of Motofen (difenoxin HCl and atropine tablets and elixir) which like Lomotil is a less-restrictive category Schedule IV on account of the adulterant; one difference is that the diphenoxylate and atropine formulation is Schedule V. Atropine is present in each dosage unit in the amount of 25 µg, or 1/40 of the therapeutic dose. Many other countries have been using this combination product for many years as a second-line centrally-acting and/or opioid-agonist anti-diarrhoeal, betwixt loperamide and paregoric.[3] The combination of difenoxin and atropine, in Schedule IV, has the DEA ACSCN of 9167 and being in Schedule IV is not assigned an aggregate annual manufacturing quota. Pure difenoxin, in Schedule I, has a quota of 50 grammes, and an ACSCN of 9168.

Side effects

Diarrhoea resulting from cyclic or diarrhoea-predominant IBS may not be optimally treated with diphenoxylate or difenoxin, and may not respond to a meaningful degree to loperamide; thus, diarrhoea and cramping which does not respond to belladonna derivatives and non-centrally-acting soothing and/or stool-desiccating agents are often treated with conservative doses of codeine, especially where paregoric and/or laudanum are not currently in general use.

Difenoxin also has some sedative and analgesic effects as with other opioids, but diphenoxylate itself is a relatively weak analgesic, and difenoxin has similarly limited analgesic effects, although it is a potent anti-diarrheal drug. Research suggests that additional non-opioid mechanisms may also be involved in the action of difenoxin, explaining its strong anti-diarrheal effects despite only limited opioid action.[4]

References

  1. Jackson LS, Stafford JE. The evaluation and application of a radioimmunoassay for the measurement of diphenoxylic acid, the major metabolite of diphenoxylate hydrochloride (Lomotil), in human plasma. Journal of Pharmacological Methods. 1987 Nov;18(3):189-97.
  2. http://www.deadiversion.usdoj.gov/schedules/orangebook/orangebook.pdf
  3. Innocenti P, Rossi L, Bombardieri G. Clinical effectiveness of difenoxine in patients with acute and chronic diarrhea. (Italian). Bollettino Chimico Farmaceutico. 1983 Dec;122(12):64S-68S.
  4. De Luca A, Coupar IM. Difenoxin and loperamide: studies on possible mechanisms of intestinal antisecretory action. Naunyn Schmiedebergs Archives of Pharmacology. 1993 Feb;347(2):231-7.

Linked-in.jpg